The Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications
Abciximab decreased mortality and target vessel revascularization when used in addition to ticlopidine and aspirin during percutaneous coronary intervention in the setting of an acute coronary syndrome.
Circulation. 2003 Sep 16;108(11):1316-23.
Purpose: To evaluate abciximab (Reopro) when added to ticlopidine and aspirin during coronary intervention in acute coronary syndromes.
Format: Double blind, multicenter, randomized control trial
Treatment Group: Abciximab and percutaneous coronary intervention (PCI)
Control Group: Percutaneous coronary intervention alone
Number of Patients: 2,082
Clinical angina or other symptoms from acute coronary syndrome for < 12 hours
ECG with > 1 mm ST elevation in 2 contiguous leads OR high grade stenosis on angiography with an associated regional wall motion abnormality
Infarct due to saphenous vein graft occlusion/stenosis
Infarct artery reference vessel < 2.5 mm in diameter
Need for urgent r emergent coronary artery bypass grafting surgically
Follow-up: 7-12 months
Primary Endpoint: Composite of all cause mortality, MI, ischemia-driven target-vessel revascularization (TVR), or stroke at 30 days
Secondary Endpoint: None